A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

NCT03905512 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Gout

Interventions

DRUG: SEL-212
DRUG: KRYSTEXXA®

Sponsor

Selecta Biosciences, Inc.